BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 23478359)

  • 21. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of killer immunoglobulin-like receptor and human leukocyte antigen class I ligand on the prognosis of related donor hematopoietic stem cell transplantation].
    Wang H; Zhai WJ; Wang HH; He Y; Zhou Z; Zhao YX; Zhai WH; Zhang RL; Wang M; Feng SZ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):533-7. PubMed ID: 19968064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
    Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
    Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome.
    Bishara A; Brautbar C; Zamir G; Eid A; Safadi R
    Hum Immunol; 2005 Nov; 66(11):1099-105. PubMed ID: 16571410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes to Predict the Occurrence of Acute Allograft Rejection after Kidney Transplantation.
    Jafari D; Nafar M; Yekaninejad MS; Abdolvahabi R; Lesan Pezeshki M; Razaghi E; Amirzargar AA
    Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):245-255. PubMed ID: 28732438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Missing Self-Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study.
    Callemeyn J; Senev A; Coemans M; Lerut E; Sprangers B; Kuypers D; Koenig A; Thaunat O; Emonds MP; Naesens M
    J Am Soc Nephrol; 2021 Aug; 32(8):2070-2082. PubMed ID: 34301794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor with HLA-C2 is associated with acute rejection following liver transplantation in Southern Chinese.
    Chen R; Yi H; Zhen J; Fan M; Xiao L; Yu Q; Yang Z; Ning L; Deng Z; Chen G
    HLA; 2022 Aug; 100(2):133-141. PubMed ID: 35509131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
    Wang H; He Y; Zhai WJ; Wang M; Zhou Z; Zhao YX; Feng SZ; Han MZ
    Swiss Med Wkly; 2013; 143():w13717. PubMed ID: 23299929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human leukocyte antigen-C in short- and long-term liver graft acceptance.
    Moya-Quiles MR; Muro M; Torío A; Sánchez-Bueno F; Miras M; Marín L; García-Alonso AM; Parrilla P; Dausset J; Alvarez-López MR
    Liver Transpl; 2003 Mar; 9(3):218-27. PubMed ID: 12619017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
    N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
    Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A
    Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
    Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
    Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.
    Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H
    Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation.
    Hanvesakul R; Kubal C; Moore J; Neil D; Cook M; Ball S; Briggs D; Moss P; Cockwell P
    PLoS One; 2011; 6(8):e23631. PubMed ID: 21912600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
    Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.